ID   LG2-MEL-205
AC   CVCL_C5UA
SY   LG-2-MEL-205
DR   Wikidata; Q116049685
RX   PubMed=2209693;
RX   PubMed=2967757;
RX   PubMed=12747754;
CC   Doubling time: 35 hours (PubMed=12747754).
CC   Sequence variation: Mutation; HGNC; HGNC:16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (PubMed=12747754).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C5U8 ! LG2-MEL
SX   Male
AG   31Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 19-12-24; Version: 5
//
RX   PubMed=2209693; DOI=10.1002/eji.1830200835;
RA   Degiovanni G., Hainaut P., Lahaye T., Weynants P., Boon T.;
RT   "Antigens recognized on a melanoma cell line by autologous cytolytic T
RT   lymphocytes are also expressed on freshly collected tumor cells.";
RL   Eur. J. Immunol. 20:1865-1868(1990).
//
RX   PubMed=2967757; DOI=10.1002/eji.1830180503;
RA   Degiovanni G., Lahaye T., Herin M., Hainaut P., Boon T.;
RT   "Antigenic heterogeneity of a human melanoma tumor detected by
RT   autologous CTL clones.";
RL   Eur. J. Immunol. 18:671-676(1988).
//
RX   PubMed=12747754;
RA   Vigneron N., Ooms A., Morel S., Degiovanni G., van den Eynde B.J.;
RT   "Identification of a new peptide recognized by autologous cytolytic T
RT   lymphocytes on a human melanoma.";
RL   Cancer Immun. 2:9-9(2002).
//